{
    "medicine_id": "94f2742c22eb77bf82a83efb3941ab8362f24d89",
    "platform_id": "DB04875",
    "metadata": {
        "name": "Belviq 10 mg 1 Tablet",
        "composition": "10 mg 1 Pralnacasan",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of rheumatoid arthritis RA",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Pralnacasan is a potent non peptide inhibitor of interleukin 1beta converting enzyme ICE Pralnacasan is an oral anti cytokine drug candidate licensed for development by Aventis Pharma from Vertex Pharmaceuticals In November 2003 Aventis and Vertex Pharmaceuticals announced that they had voluntarily suspended the phase II clinical trials of pralnacasan due to results from an animal toxicity study that demonstrated liver abnormalities after a nine month exposure to pralnacasan at high doses While no similar liver toxicity has been seen to date in human trials the companies will evaluate the animal toxicity results before proceeding with the phase II clinical program",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}